Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The RASSF1A tumor suppressor is involved in regulation of apoptosis and cell cycle progression. RASSF1A is localized to microtubules and binds the apoptotic kinases MST1 and MST2. It has been shown that this interaction is mediated by the Sav‐RASSF‐Hpo domain, which is an interaction domain characterized for the Drosophila proteins Sav (human WW45), Hpo (human MST1 and MST2) and Warts/LATS (large tumor suppressor). Previously, we have reported that RASSF1A hypermethylation occurs frequently in soft tissue sarcoma and is associated with an unfavorable prognosis for cancer patients. In our study, we performed methylation analysis of the CpG island promoter of MST1, MST2, WW45, LATS1 and LATS2 in soft tissue sarcomas by methylation‐specific PCR. No or a very low methylation frequency was detected for WW45, LATS1 and LATS2 (<7%). In 19 out of 52 (37%) sarcomas, a methylated promoter of MST1 was detected and 12 out of 60 (20%) samples showed methylation of the MST2 promoter. Methylation status of MST1 was confirmed by bisulfite sequencing. In tumors harboring a methylated promoter of MST1, a reduction of MST1 expression was observed by RT‐PCR. In leiomyosarcomas, MST1 and MST2 or RASSF1A methylation were mutually exclusive (P = 0.007 and P = 0.025, respectively). Surprisingly, a significantly increased risk for tumor‐related death was found for patients with an unmethylated MST1 promoter (P = 0.036). In summary, our results suggest that alteration of the Sav‐RASSF1‐Hpo tumor suppressor pathway may occur through hypermethylation of the CpG island promoter of MST1, MST2 and/or RASSF1A in human sarcomas. © 2007 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway
Udan, R. S., Kango-Singh, M., Nolo, R., Tao, C., & Halder, G. (2003) · Nature Cell Biology · doi:10.1038/ncb1050 · Cited by 747
The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1
Chan, E. H. Y., Nousiainen, M., Chalamalasetty, R. B., Schäfer, A., Nigg, E. A., & Silljé, H. H. W. (2005) · Oncogene · doi:10.1038/sj.onc.1208445 · Cited by 584
Cited by
The Hippo Signaling Pathway in Development and Cancer
Pan, D. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.09.011 · Cited by 2,269
The Hippo pathway and human cancer
Harvey, K. F., Zhang, X., & Thomas, D. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3458 · Cited by 1,842
The Hippo–YAP pathway in organ size control and tumorigenesis: an updated version
Zhao, B., Li, L., Lei, Q., & Guan, K.-L. (2010) · Genes & Development · doi:10.1101/gad.1909210 · Cited by 1,144
The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment
Johnson, R., & Halder, G. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4161 · Cited by 881
The Crumbs Complex Couples Cell Density Sensing to Hippo-Dependent Control of the TGF-β-SMAD Pathway
Varelas, X., Samavarchi-Tehrani, P., Narimatsu, M., Weiss, A., Cockburn, K., Larsen, B. G., Rossant, J., & Wrana, J. L. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.11.012 · Cited by 690
The Hippo signaling pathway in stem cell biology and cancer
Mo, J., Park, H. W., & Guan, K. (2014) · EMBO reports · doi:10.15252/embr.201438638 · Cited by 674
Epithelial cell polarity, stem cells and cancer
Martin-Belmonte, F., & Perez-Moreno, M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3169 · Cited by 552
The dynamic control of signal transduction networks in cancer cells
Kolch, W., Halasz, M., Granovskaya, M., & Kholodenko, B. N. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3983 · Cited by 339
Defining Driver DNA Methylation Changes in Human Cancer
Pfeifer, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041166 · Cited by 323
Self-citationYAP/TAZ Signaling as a Molecular Link between Fibrosis and Cancer
Noguchi, S., Saito, A., & Nagase, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113674 · Cited by 277
LATS2 Is a Tumor Suppressor Gene of Malignant Mesothelioma
Murakami, H., Mizuno, T., Taniguchi, T., Fujii, M., Ishiguro, F., Fukui, T., Akatsuka, S., Horio, Y., Hida, T., Kondo, Y., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2164 · Cited by 263
Regulation of TEAD Transcription Factors in Cancer Biology
Huh, H., Kim, D., Jeong, H.-S., & Park, H. (2019) · Cells · doi:10.3390/cells8060600 · Cited by 259
Kang, W., Tong, J. H. M., Chan, A. W. H., Lee, T.-L., Lung, R. W. M., Leung, P. P. S., So, K. K. Y., Wu, K., Fan, D., Yu, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2467 · Cited by 259
Alveolar rhabdomyosarcoma–associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression
Crose, L. E. S., Galindo, K. A., Kephart, J. G., Chen, C., Fitamant, J., Bardeesy, N., Bentley, R. C., Galindo, R. L., Ashley Chi, J.-T., & Linardic, C. M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67087 · Cited by 124
“In human primary soft tissue sarcomas, epigenetic downregulation has been observed in STK3/4 and LATS1 (63, 64).”
Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis
Eisinger-Mathason, T. S. K., Mucaj, V., Biju, K. M., Nakazawa, M. S., Gohil, M., Cash, T. P., Yoon, S. S., Skuli, N., Park, K. M., Gerecht, S., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420005112 · Cited by 103
The Hippo Signaling Pathway in Drug Resistance in Cancer
Zeng, R., & Dong, J. (2021) · Cancers · doi:10.3390/cancers13020318 · Cited by 89
“Due to genomic deletions or mutations (relatively rare), epigenetic silencing, or transcriptional and post-transcriptional regulations, tumor suppressors LATS1/2 and MST1/2 could undergo loss-of-function [32,33].”
BackgroundYuan, Z., Kim, D., Shu, S., Wu, J., Guo, J., Xiao, L., Kaneko, S., Coppola, D., & Cheng, J. Q. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.059675 · Cited by 78
RetractedPrevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone
Isfort, I., Elges, S., Cyra, M., Berthold, R., Renner, M., Mechtersheimer, G., Åman, P., Larsson, O., Ratner, N., Hafner, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-56247-8 · Cited by 35
Metadata
- Authors
- Seidel, C., Schagdarsurengin, U., Blümke, K., Würl, P., Pfeifer, G. P., Hauptmann, S., Taubert, H., & Dammann, R.
- Venue
- Molecular Carcinogenesis
- Publisher
- Wiley
- Published
- 2007-05-30
- Volume
- 46
- Issue
- 10
- Pages
- 865-871
- ISSN
- 0899-1987 (ISSN-L)
- 1098-2744
- OpenAlex
- W1494988280
- Cited by
- 155
- References
- 3
- FWCI
- 5.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.